Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Colorado MEDtech, CMED -- Ignore unavailable to you. Want to Upgrade?

To: DALTS who wrote (135)	10/4/1998 5:30:00 PM
From: Juli	Respond to of 288

AOL research shows .10 also. However, it shows .50 for year against .37 for last year. Three recommendations, all strong buys. Ranked number two out of 71 for medical instruments. There are three analysts covering and they all est. .50 for year. Estimate of .65 for next year. PE of 19. This still looks good to me. Jewel

To: DALTS who wrote (135)	10/9/1998 3:49:00 PM
From: Edward Larkin	Read Replies (1) \| Respond to of 288

This company has one seasonally impacted quarter a year, and it is the September quarter. The reason is due to the fact that about 1/2 of their revenues come from contract research and development for major companies. Why this effects them is simple, since most R&D projects are billed to the client on a billable hour basis, the company has less than normal hours billed in the July and August months due to most employees taking the majority of their vacation time annually during these months. The outlook remains great, ADVEST recently initiated coverage with a 65 cent estimate for 2000, and followed the concensus of 50 cents for fiscal 99. We are trading at about 12.5X the current fiscal year estimate with a 40% growth rate. If they add an an acquisition this year, the numbers will increase since none of the analysts have an acquisition built into their models.